Article
Plant Sciences
Mengjie Li, Tingting Guo, Jiayi Lin, Xia Huang, Qiaodan Ke, Yujian Wu, Chunping Fang, Chenxia Hu
Summary: Curcumin, the main pharmacological component extracted from Curcuma longa L, has been found to inhibit proliferation and metastasis of TNBC cells via the Hedgehog/Gli1 pathway, providing potential therapeutic strategies for TNBC.
JOURNAL OF ETHNOPHARMACOLOGY
(2022)
Article
Genetics & Heredity
Justine Marsolier, Pacome Prompsy, Adeline Durand, Anne-Marie Lyne, Camille Landragin, Amandine Trouchet, Sabrina Tenreira Bento, Almut Eisele, Sophie Foulon, Lea Baudre, Kevin Grosselin, Mylene Bohec, Sylvain Baulande, Ahmed Dahmani, Laura Sourd, Eric Letouze, Anne-Vincent Salomon, Elisabetta Marangoni, Leila Perie, Celine Vallot
Summary: The persistence of drug-resistant cancer cells is a major clinical challenge, particularly in triple-negative breast cancer. This study reveals that the repressive histone mark H3K27me3 plays a crucial role in regulating cell fate and chemotherapy tolerance in cancer cells. Manipulating H3K27me3 levels effectively enhances the potential of cancer cells to tolerate chemotherapy and delays tumor recurrence. These findings underscore the importance of understanding chromatin landscapes in shaping cancer cell response to initial therapy.
Article
Cell Biology
Yufeng Qi, Haodong Wu, Tianru Zhu, Zitian Liu, Conghui Liu, Congzhi Yan, Zhixuan Wu, Yiying Xu, Ying Bai, Lehe Yang, Dezhi Cheng, Xiaohua Zhang, Haiyang Zhao, Chengguang Zhao, Xuanxuan Dai
Summary: This study found that acetyl-cinobufagin can inhibit the proliferation and migration of breast cancer cells, and induce apoptosis. Acetyl-cinobufagin suppresses TNBC development by blocking the STAT3 pathway and EMT. Animal model experiments demonstrated that acetyl-cinobufagin can reduce tumor growth.
Article
Biochemistry & Molecular Biology
Lake-Ee Quek, Michelle van Geldermalsen, Yi Fang Guan, Kanu Wahi, Chelsea Mayoh, Seher Balaban, Angel Pang, Qian Wang, Mark J. Cowley, Kristin K. Brown, Nigel Turner, Andrew J. Hoy, Jeff Holst
Summary: This study reveals that glutamine-indispensable triple-negative breast cancer (TNBC) cells rely on a non-canonical glutamine-to-glutamate overflow, which increases TCA cycle fluxes and replenishes TCA cycle intermediates. The coupling of glucose and glutamine catabolism hampers TNBC cells' ability to oxidize glucose when glutamine is limiting.
Review
Oncology
Dorota Kwapisz
Summary: Triple-negative breast cancer (TNBC) is a subtype of breast cancer with poor prognosis and limited treatment options, but it shows higher immunogenicity, tumor-infiltrating lymphocytes (TILs) enrichment, and programmed cell death ligand 1 (PD-L1) expression which make it more suitable for immune checkpoint blockade therapy. Patients with PD-L1-positive TNBC subgroup may benefit the most from immune checkpoint inhibitor (ICI) treatment, and ICI given as first-line treatment in advanced TNBC shows better results than in later lines of treatment. Exciting results have been seen with pembrolizumab in early-stage TNBC, indicating potential approval in (neo)adjuvant settings in the near future.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2021)
Letter
Medicine, General & Internal
Ryan Sun, Lee-Jen Wei
Summary: This article discusses the clinical benefits of pembrolizumab combined with chemotherapy in patients with triple-negative breast cancer. The authors suggest that both hazard values and ratios should be considered when evaluating clinical benefits.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Chemistry, Medicinal
Carine M. Abdelmalek, Zexi Hu, Thales Kronenberger, Jenni Kublbeck, Franziska J. M. Kinnen, Salma S. Hesse, Afsin Malik, Mark Kudolo, Raimund Niess, Matthias Gehringer, Lars Zender, Paula A. Witt-Enderby, Darius P. Zlotos, Stefan A. Laufer
Summary: Anticancer drug conjugates that simultaneously target two receptors may overcome the limitations of current cancer treatments. A series of compounds connecting tamoxifen or endoxifen with the EGFR-inhibitor gefitinib exhibit potent anticancer activity in breast cancer cells.
JOURNAL OF MEDICINAL CHEMISTRY
(2022)
Article
Oncology
Rui Han, Hongxing Yang, Changquan Ling, Lingeng Lu
Summary: In this study, the therapeutic potential of Tiliroside (TS) in triple negative breast cancer (TNBC) was evaluated. The results showed that TS exhibited anti-cancer activity, reduced tumor burden, and improved survival rate in TNBC. Additionally, TS acted as a CAXII inhibitor to suppress TNBC progression.
CANCER CELL INTERNATIONAL
(2022)
Article
Oncology
Kurt W. Evans, Erkan Yuca, Stephen S. Scott, Ming Zhao, Natalia Paez Arango, Christian X. Cruz Pico, Turcin Saridogan, Maryam Shariati, Caleb A. Class, Christopher A. Bristow, Christopher P. Vellano, Xiaofeng Zheng, Ana Maria Gonzalez-Angulo, Xiaoping Su, Coya Tapia, Ken Chen, Argun Akcakanat, Bora Lim, Debu Tripathy, Timothy A. Yap, Maria Emilia Di Francesco, Giulio F. Draetta, Philip Jones, Timothy P. Heffernan, Joseph R. Marszalek, Funda Meric-Bernstam
Summary: Oxidative phosphorylation is a metabolic vulnerability in triple-negative breast cancer, and inhibiting it with IACS-10759 may enhance efficacy of multiple targeted therapies.
Review
Oncology
Shengye Jin, Qin Wang, Hao Wu, Da Pang, Shouping Xu
Summary: Biological therapy, particularly oncolytic viruses (OVs), has shown promising therapeutic effects in various cancers, including triple negative breast cancer (TNBC). TNBC, lacking conventional treatment targets, benefits from the emerging concept of OVs for potential treatment options.
BIOMARKER RESEARCH
(2021)
Review
Medicine, General & Internal
Jieun Lee
Summary: Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer, accounting for 15-20% of cases, with a high rate of recurrence despite chemotherapy. Conventional cytotoxic chemotherapy with anthracyclines and taxanes remains the main treatment option. Achievement of pathologic complete response (pCR) is associated with improved survival outcomes, leading to the shift towards neoadjuvant treatment and investigation of intensified chemotherapy and post-neoadjuvant therapy. This article reviews the current treatment landscape for early TNBC, from standard cytotoxic chemotherapy to immune checkpoint inhibitors, capecitabine, and olaparib.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Cell Biology
Anli Yang, Fu Peng, Lewei Zhu, Xing Li, Shunling Ou, Zhongying Huang, Song Wu, Cheng Peng, Peng Liu, Yanan Kong
Summary: Melatonin treatment downregulated FUNDC1 and lnc049808 in TNBC cell lines, which inhibited cell proliferation, invasion, and metastasis. lnc049808 and FUNDC1 acted as competing endogenous RNAs binding to miR-101, indicating a potential therapeutic pathway for TNBC progression inhibition by melatonin.
CELL DEATH & DISEASE
(2021)
Article
Cell Biology
Giulia Salvadori, Federica Zanardi, Fabio Iannelli, Riccardo Lobefaro, Claudio Vernieri, Valter D. Longo
Summary: The study demonstrates that a fasting-mimicking diet activates starvation escape pathways in TNBC cells and reduces stemness markers in CSCs, leading to decreased cell numbers and improved mouse survival. Additionally, the diet activates different survival/growth pathways in differentiated cancer cells, which can be targeted by drugs to promote tumor regression.
Article
Multidisciplinary Sciences
Zhaoping Qiu, Weijie Guo, Bo Dong, Yu Wang, Pan Deng, Chi Wang, Jinpeng Liu, Qing Zhang, Rudolf Grosschedl, Zhiyong Yu, Jiong Deng, Yadi Wu
Summary: EBF1 is highly expressed in TNBC and plays a crucial role in tumorigenicity and progression; By forming a transcriptional complex with HIF1 alpha, EBF1 regulates cell mitophagy and prevents cell death; Targeting EBF1 pathway may offer alternative treatment strategies for TNBC.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2022)
Article
Oncology
Archis Bagati, Sushil Kumar, Peng Jiang, Jason Pyrdol, Angela E. Zou, Anze Godicelj, Nathan D. Mathewson, Adam N. R. Cartwright, Paloma Cejas, Myles Brown, Anita Giobbie-Hurder, Deborah Dillon, Judith Agudo, Elizabeth A. Mittendorf, X. Shirley Liu, Kai W. Wucherpfennig
Summary: SOX4 transcription factor plays a key role in mediating resistance to T cell-mediated cytotoxicity in TNBC cells, and inhibiting it can increase the expression of genes in important immune pathways. The integrin αvβ6 receptor regulates the expression of SOX4, and targeting the integrin αvβ6-TGFβ-SOX4 pathway provides therapeutic opportunities for TNBC and other aggressive cancers of epithelial origin.
Article
Biochemistry & Molecular Biology
Ning Wei, Jun Li, Cheng Fang, Jin Chang, Vasiliki Xirou, Nick K. Syrigos, Benjamin J. Marks, Edward Chu, John C. Schmitz
Article
Medicine, Research & Experimental
Dan Dong, Zhongyi Mu, Ning Wei, Mingli Sun, Wei Wang, Na Xin, Yue Shao, Chenghai Zhao
BIOMEDICINE & PHARMACOTHERAPY
(2019)
Article
Cell Biology
Mian Chen, Yvonne Zoet, Dave Roelen, Jaume Martorell, Derek Middleton, Antonij Slavcev, Aliki Iniotaki, Frans Claas, Susan Fuggle
Article
Oncology
Xiaomei Liu, Yuxi Wang, Rong Zhang, Ting Jin, Liangliang Qu, Qianwen Jin, Jiasu Zheng, Jiaqi Sun, Ziqing Wu, Linxi Wang, Tianxu Liu, Yinxu Zhang, Xiao Meng, Ying Wang, Ning Wei
FRONTIERS IN ONCOLOGY
(2020)
Article
Polymer Science
Zhongyi Mu, Liangliang Pei, Dongbing Cao, Jing Guo, Ning Wei, Liqun Yang, Bin Hu
POLYMER DEGRADATION AND STABILITY
(2020)
Article
Oncology
Zhongyi Mu, Dan Dong, Mingli Sun, Liwen Li, Ning Wei, Bin Hu
FRONTIERS IN ONCOLOGY
(2020)
Article
Chemistry, Multidisciplinary
Gang Zhang, Daoxing Chen, Sufang Wang, Hualong Chen, Ning Wei, Guirong Chen
Article
Hematology
Zhixiang Zhu, Lili Wang, Ran Guo, Daoran Pang, Wenxuan Wang, Yan Wu, Ning Wei, Jun Li, Pengfei Tu
Summary: The natural compound XJ-8 isolated from Sanguis draxonis was found to significantly inhibit platelet activation and thrombosis by targeting MAP3K3. This suggests that XJ-8 has the potential to be developed into a novel therapeutic agent for the treatment of thrombotic diseases.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2022)
Article
Chemistry, Medicinal
Jun Li, Dayong Zheng, Ning Wei, Yunfeng Sun, Li Liu, Yuan Yuan, Qinghua Jiang
Summary: A new quassinoid, dehydrobruceantinol B, was isolated from Brucea javanica seeds, along with two known compounds, bruceantinol and bruceine A. The structure of the new compound was determined using advanced spectrometric methods. The inhibitory effects of these compounds on nitric oxide production in activated macrophages were investigated.
CHEMISTRY OF NATURAL COMPOUNDS
(2022)
Review
Pharmacology & Pharmacy
Xuepei Cai, Haokun Li, Manyi Wang, Edward Chu, Ning Wei, Jiayu Lin, Yun Hu, Jingtao Dai, Aijie Chen, Hua Zheng, Qianbing Zhang, Yuxia Zhong, Ruoshui Chang, Sha Wu, Yaomu Xiao, Chufeng Liu
Summary: Memory CD8+T cells exhibit efficient immune response, long-term survival, and continuous differentiation. Enhanced glycolytic metabolism can generate sufficient energy for the formation of these cells. The mammalian target of rapamycin (mTOR) signaling pathway regulates memory CD8+T cell formation, maintenance, and function through glycometabolism. Different subpopulations of memory CD8+T cells show metabolic flexibility during different stages, and energy metabolism may play a critical role.
BIOCHEMICAL PHARMACOLOGY
(2022)
Article
Pharmacology & Pharmacy
Ning Wei, James Burnett, Desirae L. Crocker, Yixian Huang, Song Li, Peter Wipf, Edward Chu, John C. Schmitz
Summary: Cellular protein synthesis is accelerated in human colorectal cancer, and inhibition of protein synthesis may be an effective therapeutic strategy. The quassinoid bruceantinol (BOL) showed antitumor activity and STAT3 inhibition in mouse models. BOL-resistant cell lines were sensitive to standard CRC therapeutic agents and known STAT3 inhibitors but resistant to homoharringtonine, indicating the potential of quassinoids as protein synthesis inhibitors in CRC treatment.
BIOCHEMICAL PHARMACOLOGY
(2023)
Review
Pharmacology & Pharmacy
Dayong Zheng, Jun Li, Han Yan, Gang Zhang, Wei Li, Edward Chu, Ning Wei
Summary: Aurora-A kinase plays a pivotal role in cancer progression by affecting multiple cancer hallmarks and resistance to various therapies. This review highlights the mechanisms through which Aurora-A kinase promotes therapy resistance and discusses potential strategies for targeting this kinase in combination with other therapeutic agents. Additionally, the review provides insights into the development of novel Aurora-A inhibitors for precision cancer treatment.
ACTA PHARMACEUTICA SINICA B
(2023)
Review
Biochemistry & Molecular Biology
Fernand Bteich, Mahshid Mohammadi, Terence Li, Muzaffer Ahmed Bhat, Amalia Sofianidi, Ning Wei, Chaoyuan Kuang
Summary: Colorectal cancer is a heterogeneous disease with various alterations at the cellular and molecular levels. KRAS mutations are found in up to 40% of CRCs and serve as both a prognostic and predictive biomarker. Targeting KRAS mutations in CRC is being explored through both indirect and direct strategies, with several KRAS allele-specific inhibitors in late-phase clinical trials and newer agents and targeting strategies undergoing preclinical and early-phase clinical testing.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)